|Staff Category:||Postdoctoral Fellow|
|Contract Duration:||2 years|
|Closing Date:||11 March 2018|
We are seeking to recruit an outstanding postdoctoral fellow to explore the use of droplet microfluidics for the discovery and screening of therapeutic antibodies. In particular, we are planning to screen for antibodies that do not just bind drug targets (such as GPCRs or ion channels), but rather modulate them in an agonistic or antagonistic way. Droplet microfluidic technology will allow to carry out such screens at very high throughput and furthermore facilitate the use of primary non-immortalized plasma cells from mice immunized with the drug target of interest. Ultimately, this should result in novel platform technology and first hits that can be evaluated for further development.
The position is part of a collaboration between EMBL and GSK. The successful candidate will join the Christoph Merten group at the Genome Biology Unit at EMBL Heidelberg, but will also closely interact with our industry partner GlaxoSmithKline (GSK). The candidate will be part of the EMBL Postdoctoral Program with access to training, mentorship and career development opportunities. In addition they will also benefit from participation in the GSK post-doctoral program, formal mentorship and various trainings/seminar series in drug discovery. EMBL is a leading international research organization with a collaborative and interdisciplinary atmosphere (see www.embl.de). The microfluidic platforms at EMBL are outstanding and allow multiplexed, multi-colour screens at very high throughput (e.g. sorting hundreds of thousands of droplets in a single experiment).
Qualifications and Experience
The successful candidate holds a Ph.D. in biotechnology, biology, immunology and/or microfluidic engineering. The project is particularly suitable for a postdoctoral fellow with previous experience in droplet microfluidics. The position requires exceptional motivation and commitment, the ability to work independently as well as in a team and excellent technical, organizational and management skills. A contract of 2 years, with an optional 3rd year, will be offered to the successful candidate.
Further details of the project can be obtained directly from Christoph Merten (firstname.lastname@example.org).
EMBL is an inclusive, equal opportunity employer offering attractive conditions and benefits appropriate to an international research organisation. Closing date for applications is February 28, 2018.
The EMBL is Europe’s flagship institute in the Life Sciences (ranking in the top 10 worldwide) and has a strong focus on cutting edge technologies. Major activities are in the areas of imaging and structural methods (high resolution light microscopy, cryo-EM, tissue imaging), genomics (quantitative genetics, chromatin and RNA biology, microbiome), proteomics, metabolomics, biosensors and microfluidics, embryonic development.
GSK, a science-led global healthcare company, brings to collaborations a vast knowledge around target validation and cutting-edge Drug Discovery technologies (e.g. compound libraries, screening platforms, chemoinformatics, structural biology, chemical biology/chemoproteomics). GSK acquired the EMBL spinoff Cellzome in 2012 and thus maintains a presence on the EMBL campus.
Please apply online through www.embl.org/jobs